Suggested remit: To appraise the clinical and cost effectiveness of dostarlimab with platinum-based chemotherapy within its marketing authorisation for treating primary advanced or recurrent endometrial cancer with microsatellite stable (MSS) or mismatch repair proficient (pMMR) tumours in adults.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6415

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
05 September 2024 - 03 October 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6415
05 September 2024 In progress. Scoping commencing
30 January 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
30 January 2024 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual